Relationship of metabolic syndrome defined by IDF or revised NCEP ATP III with glycemic control among Malaysians with Type 2 Diabetes

Abstract Background The chronic complications of Type 2 Diabetes (T2D) such as macrovascular disease is amplified with the increase in the number of metabolic syndrome (MetS) risk factors. This research aims to study the relationship of MetS, diagnosed by the International Diabetes Federation (IDF) or revised National Cholesterol Education Programs Adult Treatment Panel III (NCEP ATP III) criteria, with glycemic control, Fasting blood glucose (FBG), glycated hemoglobin (HbA1c), C-peptide, and insulin resistance in T2D patients.Methods The study is a cross-sectional observational study which, involved 485 T2D patients who are receiving treatment at the University Kebangsaan Malaysia Medical Center (UKMMC), Kuala Lumpur, Malaysia. The MetS among the T2D patients was diagnosed based on IDF and revised NCEP ATP III criteria. C-peptide and HbA1c levels were determined by an automated quantitative immunoassay analyzer and high-performance liquid chromatography, respectively. The MetS factors; FBG, triglyceride, and high-density lipoprotein cholesterol were measured by spectrophotometer. Results Application of the IDF and revised NCEP ATP III criteria respectively resulted in 73% and 85% of the T2D subjects being diagnosed with MetS. The concordance of these criteria in diagnosing MetS among T2D patients was low (κ =0.33, P<0.001). Both IDF and revised NCEP ATP III criteria indicated that T2D patients with 5 MetS factors had higher insulin resistance (P=2.1×10-13;1.4×10-11), C-peptide (P=1.21×10-13; 4.1×10-11), FBG (P=0.01; 0.021), and HbA1c (P=0.039; 0.018) than those T2D patients without MetS, respectively. Conclusion Although there is a low concordance between IDF and revised NCEP ATP III criteria in the diagnosis of MetS among T2D patients, both criteria showed that T2D patients with 5 MetS factors had higher insulin resistance, C-peptide, FBG, and HbA1c.

Download Full-text

The Impact of Metabolic Syndrome Defined by IDF or Revised NCEP on Glycemic control in Malaysians with Type 2 Diabetes

10.21203/rs.3.rs-27358/v1 ◽

2020 ◽

Author(s):

Riyadh Saif-Ali ◽

Nor Azmi Kamaruddin ◽

Molham AL-Habori ◽

Sami A Al-Dubai ◽

Wan Zurinah Wan Ngah

Keyword(s):

Insulin Resistance ◽

Type 2 Diabetes ◽

Metabolic Syndrome ◽

Blood Glucose ◽

Glycemic Control ◽

Diabetic Patients ◽

C Peptide ◽

The Metabolic Syndrome ◽

Type 2 Dm

Abstract BackgroundChronic complication of Type 2 diabetes mellitus such as macrovascular disease is amplified with the increase in the number of the metabolic syndrome (MeS) risk factors. Specific criteria for diagnosis of metabolic syndrome are essential to help in glycemic control and reduce cardiovascular morbidity and mortality in diabetic patients with metabolic syndrome.Methods The study involved 485 Type 2 DM patients who are receiving treatment at the University Kebangsaan Malaysia Medical Center (UKMMC), Kuala Lumpur, Malaysia. Metabolic syndrome among the Type 2 DM patients was diagnosed based on IDF and NCEP-R criteria. The C-peptide and glycated hemoglobin (HbA1c) levels were determined by an automated quantitative immunoassay analyzer and high-performance liquid chromatography respectively. The metabolic syndrome factors, glucose, triglyceride and HDL cholesterol were measured by spectrophotometerResultsApplication of IDF and NCEP-R criteria respectively resulted in 73% and 85% of Type 2 DM subjects being diagnosed with metabolic syndrome. The concordance of these criteria in diagnosing metabolic syndrome among Type 2 DM was low (kappa=0.33, P<0.001). Both IDF and NCEP-R criteria indicated that Type 2 DM with five criteria of metabolic syndrome had higher insulin resistance (P=2.1×10-13, P=1.4×10-11), C-peptide (P=1.21×10-13; 4.1×10-11), blood glucose (P=0.01; 0.021) and HbA1c (P=0.039; 0.018) than those Type 2 DM without metabolic syndrome respectively.ConclusionHowever, there is a low concordance between IDF and NCEP-R criteria in the diagnosis of metabolic syndrome among Type 2 DM, both criteria showed that type 2 DM with five criteria of metabolic syndrome had higher insulin resistance, blood glucose and HbA1c.

Download Full-text

Relationship of Metabolic Syndrome Defined by IDF or Revised NCEP with Glycemic Control among Malaysians with Type 2 Diabetes

10.21203/rs.3.rs-27358/v2 ◽

2020 ◽

Author(s):

Riyadh Saif-Ali ◽

Nor Azmi Kamaruddin ◽

Molham AL-Habori ◽

Sami A Al-Dubai ◽

Wan Zurinah Wan Ngah

Keyword(s):

Insulin Resistance ◽

Type 2 Diabetes ◽

Metabolic Syndrome ◽

Blood Glucose ◽

Glycemic Control ◽

Diabetic Patients ◽

C Peptide ◽

The Metabolic Syndrome ◽

Cardiovascular Morbidity And Mortality

Abstract Background Chronic complication of Type 2 Diabetes (T2D) such as macrovascular disease is amplified with the increase in the number of the metabolic syndrome (MetS) risk factors. Specific criteria for diagnosis of MetS are essential to help in glycemic control and reduce cardiovascular morbidity and mortality in diabetic patients with metabolic syndrome.Methods The study is cross-sectional observational study which involved 485 T2D patients who are receiving treatment at the University Kebangsaan Malaysia Medical Center (UKMMC), Kuala Lumpur, Malaysia. Metabolic syndrome among the T2D patients was diagnosed based on IDF and NCEP-R criteria. C-peptide and glycated hemoglobin (HbA1c) levels were determined by an automated quantitative immunoassay analyzer and high-performance liquid chromatography, respectively. The metabolic syndrome factors, glucose, triglyceride and HDL cholesterol were measured by spectrophotometer Results Application of IDF and NCEP-R criteria respectively resulted in 73% and 85% of T2D subjects being diagnosed with MetS. The concordance of these criteria in diagnosing MetS among T2D was low (κ =0.33, P<0.001). Both IDF and NCEP-R criteria indicated that T2D with five criteria of MetS had higher insulin resistance (P=2.1×10-13, P=1.4×10-11), C-peptide (P=1.21×10-13; 4.1×10-11), blood glucose (P=0.01; 0.021) and HbA1c (P=0.039; 0.018) than those T2D without MetS respectively. Conclusion Although, there is a low concordance between IDF and NCEP-R criteria in the diagnosis of MetS among T2D, both criteria showed that T2D with five criteria of MetS had higher insulin resistance, blood glucose and HbA1c.

Download Full-text

The effects of metformin plus sulfonylurea therapy on clinical features of the metabolic syndrome

Medicinski pregled ◽

10.2298/mpns1010611k ◽

2010 ◽

Vol 63 (9-10) ◽

pp. 611-615 ◽

Cited By ~ 1

Author(s):

Branka Koprivica ◽

Teodora Beljic-Zivkovic ◽

Tatjana Ille

Keyword(s):

Insulin Resistance ◽

Blood Pressure ◽

Type 2 Diabetes ◽

Metabolic Syndrome ◽

Body Mass Index ◽

Waist Circumference ◽

Glycemic Control ◽

Body Mass ◽

Combined Therapy

Introduction. Insulin resistance is a well-known leading factor in the development of metabolic syndrome. The aim of this study was to evaluate metabolic effects of metformin added to sulfonylurea in unsuccessfully treated type 2 diabetic patients with metabolic syndrome. Material and methods. A group of thirty subjects, with type 2 diabetes, secondary sulfonylurea failure and metabolic syndrome were administered the combined therapy of sulfonylurea plus metformin for six months. Metformin 2000 mg/d was added to previously used sulfonylurea agent in maximum daily dose. Antihypertensive and hypolipemic therapy was not changed. The following parameters were assessed at the beginning and after six months of therapy: glycemic control, body mass index, waist circumference, blood pressure, triglycerides, total cholesterol and its fractions, homeostatic models for evaluation of insulin resistance and secretion (HOMA R, HOMA B) and C- peptide. Results. Glycemic control was significantly improved after six months of the combined therapy: (fasting 7.89 vs. 10.61 mmol/l. p<0.01; postprandial 11.12 vs. 12.61 mmol/l. p<0.01, p<0.01; glycosylated hemoglobin 6.81 vs. 8.83%. p<0.01). the body mass index and waist circumference were significantly lower (26.7 vs. 27.8 kg/m2, p<0.01 and 99.7 vs. 101.4 cm for men, p<0.01; 87.2 vs. 88.5 for women, p<0.01). Fasting plasma triglycerides decreased from 3.37 to 2.45 mmol/l (p<0.001) and HOMA R from 7.04 to 5.23 (p<0.001). No treatment effects were observed on blood pressure, cholesterol, and residual insulin secretion. Conclusion. Administration of metformin in type 2 diabetes with metabolic syndrome decreased cardiovascular risk factors by reducing glycemia, triglycerides, BMI, central obesity and insulin resistance.

Download Full-text

Serum Sex Hormone Binding Globulin (SHBG) Relation with Different Components of Metabolic Syndrome in Men with Type 2 Diabetes

Hormone and Metabolic Research ◽

10.1055/s-0043-123348 ◽

2017 ◽

Vol 50 (02) ◽

pp. 138-144 ◽

Cited By ~ 2

Author(s):

Khalid Siddiqui ◽

Khalid Al-Rubeaan ◽

Shaik Nawaz ◽

Khaled Aburisheh ◽

Anas Alaabdin ◽

...

Keyword(s):

Type 2 Diabetes ◽

Metabolic Syndrome ◽

Fasting Blood Glucose ◽

International Diabetes Federation ◽

Free Testosterone ◽

Gonadal Hormones ◽

Sex Hormone ◽

Sex Hormone Binding Globulin ◽

Hormone Binding

AbstractSex hormone binding globulin (SHBG) is demonstrated to be decreased in subjects with metabolic syndrome (MetS). The aim of the present study was to investigate the association of SHBG in relation to MetS components among men with type 2 diabetes (T2D). This cross-sectional study was carried out among 429 Saudi T2D male patients aged >30 years. Metabolic syndrome was defined using International Diabetes Federation (IDF) criteria. Fasting blood glucose (FBG), HbA1c, albumin, and lipid parameter were measured. Gonadal hormones, namely total testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and SHBG were determined using ELISA. The SHBG levels of the MetS group was significantly lower than non-MetS group 47.25±31.03 nmol/l vs. 56.55±37.84 nmol/l; p=0.013. As the MetS score increases, SHBG and HDL levels decrease while weight, BMI, waist circumference, SBP, DBP, FBG, HbA1c, TC, and TG levels increase. SHBG correlated with age, BMI, TG, HDL, TT, free testosterone, and bio-available testosterone. This is the first study that provides detailed analyses of SHBG with MetS components in male diabetic subjects. The mean serum SHBG levels gradually declined with the addition of MetS components in T2D men. TT, free testosterone, and bio-available testosterone remained independently associated with SHBG by multivariable regression analysis.

Download Full-text

Relationship of metabolic syndrome defined by IDF or revised NCEP ATP III with glycemic control among Malaysians with Type 2 Diabetes

Diabetology & Metabolic Syndrome ◽

10.1186/s13098-020-00575-7 ◽

2020 ◽

Vol 12 (1) ◽

Author(s):

Riyadh Saif-Ali ◽

Nor Azmi Kamaruddin ◽

Molham AL-Habori ◽

Sami A. Al-Dubai ◽

Wan Zurinah Wan Ngah

Keyword(s):

Type 2 Diabetes ◽

Metabolic Syndrome ◽

Glycemic Control ◽

Relationship Of

Download Full-text

The Effectiveness of Myo-Inositol and D-Chiro Inositol Treatment in Type 2 Diabetes

International Journal of Endocrinology ◽

10.1155/2016/9132052 ◽

2016 ◽

Vol 2016 ◽

pp. 1-5 ◽

Cited By ~ 26

Author(s):

Basilio Pintaudi ◽

Giacoma Di Vieste ◽

Matteo Bonomo

Keyword(s):

Insulin Resistance ◽

Type 2 Diabetes ◽

Side Effects ◽

Glycemic Control ◽

Fasting Blood Glucose ◽

Glucose Lowering ◽

Insulin Mimetic ◽

Safe Strategy ◽

Significant Difference

Inositol has been used as a supplement in treating several pathologies such as PCOS, metabolic syndrome, and gestational diabetes. Both myo-inositol and its isomer d-chiro-inositol showed insulin mimetic effects in conditions of insulin resistance. Type 2 diabetes (T2DM) is a condition typically caused by insulin resistance. There is a lack of evidence of inositol use in T2DM. We evaluated the effectiveness and safety of myo-inositol and d-chiro-inositol treatment in T2DM. This was a pilot study involving a consecutive sample of patients with T2DM with suboptimal glycemic control (HbA1c 7.0–10.0%) already treated with glucose-lowering agents. Patients (23.1% males, mean age of60.8±11.7years) took for three months a combination of myo-inositol (550 mg) and d-chiro-inositol (13.8 mg) orally twice a day as add-on supplement to their glucose-lowering drugs. Possible occurrence of side effects was investigated. After three months of treatment fasting blood glucose (192.6±60.2versus160.9±36.4;p=0.02) and HbA1c levels (8.6±0.9versus7.7±0.9;p=0.02) significantly decreased compared to baseline. There was no significant difference in blood pressure, lipid profile, and BMI levels. None of the participants reported side effects. In conclusion, a supplementation with a combination of myo- and d-chiro-inositol is an effective and safe strategy for improving glycemic control in T2DM.

Download Full-text

KORELASI INDEKS 20/(C-PEPTIDE PUASA×GLUKOSA DARAH PUASA) DENGAN HOMA-IR UNTUK MENILAI RESISTENSI INSULIN DIABETES MELITUS TIPE 2

Majalah Kedokteran Andalas ◽

10.22338/mka.v38.i4.p155-164.2015 ◽

2016 ◽

Vol 38 (4) ◽

pp. 155

Author(s):

Elsi Kelana ◽

Ellyza Nasrul ◽

Rismawati Yaswir ◽

Desywar Desywar

Keyword(s):

Insulin Resistance ◽

Type 2 Diabetes ◽

Insulin Secretion ◽

Blood Glucose ◽

Pearson Correlation ◽

Fasting Blood Glucose ◽

Biological Response ◽

Fasting Insulin ◽

C Peptide

AbstrakResistensi insulin merupakan penurunan respons biologis jaringan terhadap insulin dalam kadar normal. Pada DM tipe 2 terjadi resistensi dan gangguan sekresi insulin. Terdapat indeks baru 20/(C-peptide puasa x glukosa darah puasa) untuk menilai resistensi sekaligus gangguan sekresi insulin. Penelitian bertujuan membuktikan korelasi indeks 20/(C-peptide puasa x glukosa darah puasa) dengan HOMA-IR untuk menilai resistensi insulin pada DM tipe 2 di RSUP. Dr. M. Djamil Padang. Dengan menggunakan sampel darah dari pasien, kadar glukosa darah puasa, insulin puasa dan C-peptide puasa ditentukan. Data yang diperoleh kemudian dianalisis menggunakan korelasi Pearson. Hasil penelitian menunjukkan rerata kadar glukosa puasa 9,83 (3,53) mmol/L [177 (63,54) mg/dL], insulin puasa 10,58 (3,61) μU/L, dan C-peptide puasa 0,97 (0,29) nmol/L dan terdapat korelasi yang sangat kuat dan bermakna secara statistik (p<0,0001) antara indeks 20/(C-peptide puasa x glukosa darah puasa) dengan HOMA-IR (r= -0,838). Dapat disimpulkan bahwa indeks 20/(C-peptide puasa x glukosa darah puasa) dan HOMA–IR berkorelasi kuat untuk menilai resistensi insulin pada DM tipe 2 di RSUP. Dr. M. Djamil Padang.AbstractInsulin resistance is a decrease of biological response of the tissues to the normal level of insulin. In type 2 diabetes, there is resistance and impaired of insulin secretion. There is a new index available to assess resistance and impaired of insulin secretion all at once, with the formula 20/(fasting C-peptide x fasting blood glucose). This study aimed to prove the correlation of this new index to the HOMA-IR (Homeostasis model assesment of insulin resistance) in type 2 diabetes at Dr.M.Djamil Padang hospital. Level of fasting glucose, fasting insulin and fasting C-peptide of blood were measured, followed by statistical data analysis using Pearson correlation test.The result showed the mean of fasting blood glucose, fasting insulin and fasting C-peptide were 9.83 (3.53) mmol/L[177 (63.54) mg/dl], 10.58 (3.61) μU/L, and 0.97 (0.29) nmol/L respectively.There was a strong and statistically significant correlation (p<0.0001) found between the new index and the HOMA-IR ( r= -0.838). To be concluded, the index 20/(fasting C-peptide x fasting blood glucose) and HOMA-IR was strongly correlated to assess insulin resistance in type 2 diabetes at Dr. M. Djamil Padang hospital.

Download Full-text

Multi-electrode endovascular denervation at a new site of celiac artery for glycemic control in patients with type 2 diabetes mellitus: a promisingly primary result

10.21203/rs.3.rs-357352/v1 ◽

2021 ◽

Author(s):

Tao Pan ◽

Qiong Wei ◽

Zhi Wang ◽

Qi Zhang ◽

Yue Qian ◽

...

Keyword(s):

Diabetes Mellitus ◽

Insulin Resistance ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Glycemic Control ◽

Abdominal Aorta ◽

Celiac Artery ◽

C Peptide ◽

Catheter System

Abstract Background: Although renal denervation (RDN) may theoretically be effective on type 2 diabetes mellitus (T2DM), most clinical data failed to demonstrate such a concept. We investigated the safety and primary effects of catheter-based endovascular denervation (EDN) at new sites of the celiac artery (CA), and the abdominal aorta around CA using a novel multi-electrode device on glycemic control in T2DM patients. Methods: With a novel six-electrode catheter system, EDN was conducted in T2DM patients at new sites of CA and aorta between CA and superior mesenteric artery (SMA) in purpose of targeting on the postganglionic efferent nerves innervating the liver, islet, and other metabolic organs. The major inclusion criteria were T2DM patients diagnosed over 5 years, with hemoglobin A1c (HbA1c) over 7.5%. The primary outcomes were evaluated by the safety, HbA1c, homeostasis-model assessment of insulin resistance (HOMA-IR), fasting plasma glucose (FPG), 2-hour postprandial plasma glucose (2hPG), and oral glucose tolerance test (OGTT) based 3-hour C-peptide test. The antidiabetic medication, lifestyle, physical condition, blood pressure (BP), plasma norepinephrine, angiotensin II, liver biochemistry, and plasma lipids were also recorded.Results: A total of 11 patients were included for analysis. The technical success was 100% and no severe treatment-related adverse events or major complications were observed. Both HbA1c and HOMA-IR significantly reduced at 6 months (9.9 vs. 8.0, P = 0.005; 13.3 vs. 6.0, P = 0.016, respectively). Decreases of FPG and 2hPG were observed (15.4 vs.10.1 mmol/L, P < 0.001; 17.9 vs. 11.4 mmol/L, P = 0.001, respectively). OGTT based C-peptide test indicated improved beta-cell function ([AUC] 0.23 vs. 0.28 pmol/mL, P =0.046). A reduction of daily insulin injection (P = 0.02) and improvement of liver function (ALT, P = 0.014; GGT, P = 0.021) were also observed without changes in lifestyle, physical conditions, and other metabolic measurements.Conclusions: The 6-month analysis of this trial showed that EDN at new sites of CA and the abdominal aorta around celiac artery using the novel six-electrode catheter system elicits a clinically significant improvement in glycemic control and insulin resistance in patients with T2DM, with good tolerability. Trial Registration Number NCT 04086043, dated 11/9/2019.

Download Full-text